The biotechnology company's stock rose about 2.8
percent in light trading before the bell on Thursday.
Isis said patients treated with a 300 mg dose of the drug, ISIS-FXIRx,
experienced a significantly lower incidence of blood clots in their
veins, compared to patients given the approved anticoagulant,
enoxaparin, in a mid-stage study.
ISIS-FXIRx targets Factor XI, a clotting factor produced in the
liver. High levels of Factor XI raises the risk of thrombosis, a
condition where abnormal blood clot formation could lead to heart
attacks and strokes.
The trial was evaluating 200 mg and 300 mg doses of Isis's treatment
against enoxaparin in 300 patients.
The company said the 200 mg dose did not show any significant
benefit over enoxaparin.
The Carlsbad, California-based company's shares closed at $23.20 on
the Nasdaq on Wednesday.
[to top of second column]
(Reporting by Natalie Grover in Bangalore; Editing
by Savio D'Souza)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.